



Part of #14

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

6/25/01
Date

Jennifer L. Turnell

RECEIVED

JUL 11 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re Application of:
Gerard F. Barry *et al.*

Serial No.: 09/464,099

Filed: December 16, 1999

For: GLYPHOSATE-TOLERANT 5-
ENOLPYRUVYLSHIKIMATE 3-
PHOSPHATE SYNTHASES

Examiner: G. Ewoldt

Group Art Unit: 1644

Atty. Dkt. No.: 11899.0175.DVUS01
(MOBT:175-2)

**SUBSTITUTE SEQUENCE LISTING AND
STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.825(a) AND (b)
AND STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(g)**

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a substitute computer readable form and a substitute paper copy of the sequence listing of those sequences in the captioned patent application, wherein one sequence has been added (SEQ ID NO:70). The added SEQ ID NO:70 is supported in the original specification at page 53, lines 15-16 in conjunction with Figure 3 (SEQ ID NO. 3). SEQ ID NO:3 is the amino acid sequence for the protein encoded by the CP4 EPSPS coding sequence (SEQ ID NO:2). The cited text at page 53 of the specification indicates that the CP4 EPSPS

coding region was modified such that the resulting protein has a Leucine at position 2 instead of a Serine. This change to position 2 is now reflected in added SEQ ID NO:70.

Please amend the specification by deleting the original sequence listing and insert this substitute sequence listing.

The substitute computer readable form of the sequence listing is the same as the substitute paper copy of the sequence listing. The sequence information provided in the specification is also the same as the sequence listing of the enclosed substitute computer readable and paper forms of the sequence listing.

In accordance with 37 C.F.R. § 1.821(g), it is herewith represented that no new matter is included with this submission.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from our Deposit Account No. 01-2508/11899.0175.DVUS01.

Respectfully submitted,



Patricia A. Kammerer
Reg. No. 29,775

HOWREY SIMON ARNOLD & WHITE, LLP
750 Bering Drive
Houston, Texas 77057-2198
(713) 787-1400

Attorney for Assignee
MONSANTO COMPANY

Date: June 25, 2001